Acutus Medical Secures FDA Clearance and CE Mark for SuperMap™

Announces First Procedures in U.S. and Initial Experience in EU

Acutus Medical today announced FDA clearance and CE Mark of SuperMap™ – a revolutionary addition to its AcQMap 3D Imaging and Mapping System. SuperMap is a high-fidelity, high-resolution mapping algorithm for both stable and transient arrhythmias. SuperMap’s user interface effortlessly guides electrophysiologists to quickly create exquisitely detailed whole-chamber maps of the left or right atrium using its unique non-contact roving “hover-map” approach.

This allows electrophysiologists to diagnose and treat arrhythmia patients rapidly, consistently and potentially more effective.  Adding the SuperMap mode to the AcQMap system enables users to visualize any atrial rhythm in under three minutes. Rapidly mapping and re-mapping the whole heart chamber facilitates a new procedural workflow in EP ablation — by making it practical to execute an iterative “map, ablate, re-map” approach to diagnosis and therapy.

With this groundbreaking addition, Acutus Medical delivers the only EP imaging and mapping system to offer three mapping modalities: contact mapping, non-contact mapping, and non-contact hover mapping — known as SuperMap.

Initial Experience EU*: “In less than three minutes, the AcQMap System can map the entire chamber to clearly identify re-entrant circuits, regions of slow conduction and focal origins. The Automatic Beat Grouping algorithm of SuperMap is helpful to map alternating or changing atrial tachycardias by categorizing and displaying multiple tachycardias occurring at the same time,” said Dr. Tom Wong, Electrophysiologist, Royal Brompton & Harefield NHS Foundation Trust, London, England.

“Dynamic atrial substrate characterization is an emerging diagnostic strategy involving the mapping of sinus and paced rhythms to identify clinically relevant areas of slow conduction, lines of block and critical zones of irregular activity. These areas may correlate with arrhythmia initiation or maintenance. SuperMap is the ideal tool for implementing this strategy. Within seconds, I can review the maps and identify zones of slow conduction,” said Dr. Gian-Battista Chierchia, Electrophysiologist, Vrije Universiteit Brussel, Brussels, Belgium.

First Cases in the U.S.:  “It is critical to map repetitive rhythms in patients with irregular heartbeats. This approach is extremely helpful in identifying areas of low amplitude which may indicate scar. I am looking forward to integrating new technology into my workflow for the treatment of any arrhythmia,” stated Gregory Feld, MD, Professor of Medicine at UC San Diego School of Medicine and director of the Cardiac Electrophysiology Program at UC San Diego Health.

“We recently completed an extraordinary case with the Acutus system and SuperMap. We captured three whole-chamber maps, targeted three ablation sites, and the patient left in sinus rhythm — all in the span of one hour,” said Arjun Gururaj, MD, Electrophysiologist, Nevada Heart & Vascular Center in Las Vegas, Nevada. “These are notoriously complex atrial tachycardias that the EP community knows about. SuperMap can show potential sources and likely mechanisms in those complex cases in minutes as opposed to hours with conventional systems — because we are seeing things that we couldn’t see before.  Now we may be able to do something about it in far less time with better acute results. It has amazing potential.”

Vince Burgess, President & CEO of Acutus Medical commented, “We have invested heavily in developing a unique, multifunctional mapping system that provides physicians with the visual information needed to effectively diagnose and treat patients. With three distinct and unique mapping modalities in one system, physicians can feel confident in tackling any atrial arrhythmia accurately and efficiently. We are committed to improving patient outcomes, expediting procedures times and further developing our full suite of products for the global electrophysiology community.”

*The AcQMap System with SuperMap was CE Marked in October of 2019.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy